ALK and non-small cell lung carcinoma: Based on the results of ASCEND-4 and ASCEND-8 studies, the FDA and China National Medical Products Administration approved ceritinib as first-line treatment for patients with advanced NSCLC with ALK fusions in May 2017 and May 2020, respectively.